Single-agent paclitaxel in patients with previously untreated stage IV epithelial ovarian cancer

British Journal of Cancer

Volumn 75, Issue 5, 1997, Pages 710-714

  Gore, M E ^a   Rustin, G ^b   Slevin, M ^c   Gallagher, C ^c   Penson, R ^c   Osborne, R ^d   Ledermann, J ^e   Cameron, T ^f   Thompson, J M ^f  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b MOUNT VERNON HOSPITAL   (United Kingdom)

^c ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^d POOLE HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

^e MIDDLESEX HOSPITAL   (United Kingdom)

^f BRISTOL MYERS SQUIBB   (United States)

Author keywords

Ovarian cancer; Paclitaxel; Stage IV

Indexed keywords

CARBOPLATIN; PACLITAXEL;

ADULT; AGED; ALOPECIA; ARTHRALGIA; ARTICLE; BONE PAIN; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; DRY EYE; EDEMA; FATIGUE; FEMALE; HUMAN; INFECTION; INTRAVENOUS DRUG ADMINISTRATION; MUCOSA INFLAMMATION; MULTICENTER STUDY; MYALGIA; NAUSEA; NEUROTOXICITY; NEUTROPENIA; OTOTOXICITY; OVARY CANCER; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; VOMITING;

EID: 0031047792     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1997.126     Document Type: Article

References (24)

1. Alberts DS, Dahlberg S, Green SJ, Garcia D, Hannigan EV, O'Toole R, Stock-Novack D, Surwit EA, Malviya VK and Jolles CJ (1993) Analysis of patient age as an independent prognostic factor for survival al in a phase III study of cisplatin and cyclophosphamide versus carboplatin and cyclophosphamide in stages III (suboptimal) and IV ovarian cancer. A Southwest Oncology Group Study. Cancer 71: 618-627
2. Aravantinos G, Skalos D, Kosmidis P, Athanasiadis A. Bafaloukos D, Giannakakis TH, Papantonakis E and Fountzilas G (1994) Taxol in platinum preireated ovarian cancer patients (preliminary results). Ann Oncol 5 (suppl. 8): 102
3. Athanassiou A, Pectasides D, Varthalitis I, Dimitriades M, Tsiliakos S and Papazachariou A (1994) Taxol (T) Patients (PTS) with Cis (C)/Carbo (CA) platin-refractory ovarian carcinoma (OC). Proc Am Soc Clin Oncol 13: 870
4. Belani CP, Egorin MJ, Hiponia C, Hiponia D, Engstrom C, Hussain A and Aisner J (1994) Phase I pharmacokinetic and pharmaco-dynamic study of taxol and carboplatin (CBDCA) plus Filagrastin (G-CSF) support in metaslatic non-small cell lung cancer (NSCLC) (abstract). Ann Oncol 5 (suppl. 5): 487
5. Einzig AI, Wiernik PH, Sasloff J, Sasloff J, Runowicz CD and Goldberg GL (1992) Phase II study and long-term follow-up of patients treated with Taxol for advanced ovarian adenocarcnioma. J Clin Oncol 10: 1748-1753
6. Eisenhauer EA, ten Bokkel Huinink WW, Swenerton KD, Gianni L, Myles J, van der Burg MEL, Kerr I, Venmorken JB, Bosen K, Colombo N, Bacon M, Santabarbara P, Onetto N, Winograd B and Canetta R (1994) European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion. J Clin Oncol 12: 2654-2666
7. Gore ME, Levy V, Rustin G, Perren T, Calvert AH, Earl H and Thompson JM (1995a) Paclitaxel (Taxol) in relapsed and refractory ovarian cancer: the UK & Eire experience. Br J Cancer 72: 1016-1019
8. Gore ME, Preston N, A;Hern RP, Hill C, Mitchell P, Chang J and Nicolson M (1995b) Platinum non-cross resistance in epithelial ovarian cancer. Br J Cancer 71: 1308-1310
9. Hogberg T, Carstensen J and Simonson E (1993) Treatment results and prognostic factors in a population-based study of epithelial ovarian cancer, Gynecol Oncol 48: 38 49
10. International Federation of Gynaecology and Obstetrics (1998) Changes in definitions of clinical staging for carcinoma of the cervix and ovary. Am J Obstet Gynecol 156: 236-241
11. Kavanagh JJ. Kudelka AP, Edwards CL, Freedman RS, Gibbs H, Gonzalez de Leon C, Canetta R, Harper KJ, Kopplin S and Mante R (1993) A randomized crossover trial of parenteral hydroxyurea vs. high dose Taxol in cisplatin/carboplatin resistant epithelial ovarian cancer. Proc Am Soc Clin Oncol 12: 822.
12. Kohn EC. Sarosy G, Bicher A, Link C, Christian M, Steinberg SM, Rothenberg M, Adamo DO, Davis P and Ognibene FP (1994) Dose intense taxol: high response rate in patients with platinum-resistant recurrent ovarian cancer, J Natl Cancer Inst 86: 18-24
13. McGuire WP, Hoskins WJ, Brad MF, Homesley HD. Creasman WT, Berman ML, Ball H, Berek JS and Woodward J. (1995) Assessment of dose-intensive therapy in suboptimally debulked ovarian cancer: a gynaecologic oncology group study. J Clin Oncol 13: 1589-1599
14. McGuire WP, Hoskins WJ, Brady MF, Homesley HD, Creasman WT, Herman ML, Ball H, Berek JS and Woodward J (1996) Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Eng J Med 334: 1-6
15. Markman M, Hakes T, Reichman B, Schneider J, Rubin S, Lewis J, Barakat R, Curtin J. Jones W and Almadroner L (1993) Memorial Sloane Kettering (MSKCC) experience with National Cancer Institute (NCI) treatment referral centre protocol 9103: taxol in refractory ovarian cancer (ROC). Proc Am Soc Clin Oncol 12: 851
16. Neijt JP, ten Bokkel Huinink WW, Van derBurg MKL, Van Oosterom AT, Willemse PH, Vermorken JB, Van Lindert AC, Heintz AP, Aartsen E and Van Lent M (1991) Long-term survival in ovarian cancer. Eur J Cancer 27: 1367-1372
17. Ozols RF, Kilpatrick D, O'Dwyer P, Johnson S, Bookman MA, Walsezak J, Rowinsky E and McGuire W (1993) Phase I and pharmacokinetic study of taxol (T) and carboplatin (C) in previously untreated patient (PTS) with advanced epithelial ovarian cancer (OC): a pilot study of the Gynecologic Oncology Group. Proc Am Soc Clin Oncol 12: 824
18. Perren TJ, Wiltshaw E, Harper P, Slevin M, Stein R, Tan S, Gore M, Fryatt IJ and Blake PR (1993) A randomised study of carboplatin vs sequential ifoslamide/carboplatin for patients with FIGO stage III epithelial ovarian carcinoma, Br J Cancer 68: 1190-1194
19. Pettersson F, Coppleson M, Creasman W, Ludwig M and Shepherd J (1988) Annual Report on the Results of treatment in Gynaecological Cancer. Vol. 20. International Federation of Gynaecology and Obstetrics
20. Seewaldt VL, Greer BE, Cain JM, Figge DC, Tamimi HK, Brown WS and Miller SA (1994) Paclitaxel (Taxol) treatment for refractory ovarian cancer: phase II clinical trial. Am J Obstet Gynecol 170: 1666-1671
21. ten Bokkel Huinink WW, Veenhof CHN, Huizing M. Rodenhuis S, Dubbelman R, Dalesio O, Beijnen JH. Depauw L and Winograd B (1994) Carboplatin and Paclitaxel (Taxol) in patients with advanced ovarian cancer, a dose finding study (abstract). Ann Oncol 5 (suppl. 8): 0495
22. Thigpen JT, Blessing JA, Ball H, Hummel SJ and Barrett RJ (1994) Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a gynecologic oncology group study. J Clin Oncol 12: 1748-1753
23. Trimble EL, Adams JD, Vena D, Hawkins MJ, Friedman MA, Fisherman JS, Christian MC. Canetta R, Onetto N and Hayn R (1993) Paclitaxel for platinum-refractory ovarian cancer: results from the first 1,000 patients registered to National Cancer Institute Treatment Referral Centre 9103. J Clin Oncol 11: 2405-2410
24. Uziely B, Groshen S, Jeffers S, Morris M, Russel C, Roman L, Muderspach L and Muggia F (1994) Paclitaxel (Taxol) in heavily ovarian cancer: antituniour activity and complications. Ann Oncol 5: 827-833